Tecelra Injection, Suspension
Product Images NDC 83205-0001

This is a description of "afamitresgene autoleucel," a medication designed for autologous and intravenous use. It contains a specific dosage of MAGE-A4 TCR positive T cells in a frozen suspension with 5% DMSO. The product should be gently mixed post-thaw before intravenous infusion. It is important to follow the full prescribing information for administration. The medication must be stored and transported at or below -130°C. The product is genetically modified, and it is advised not to use a leukodepleting filter or irradiate it. It has not been evaluated for infectious substances. The manufacturer is Adsptmmune LLC based in Pennsylvania, USA. For more information or assistance, contact them at the provided phone number.*

The text provides information about a medical product called afamitresgene autoleucel with identifiers such as Patient MRN, COID, First Name, Last Name, OB, BIN, Exp, and Lot. The expiry date for this product is December 31, 2024. Additional details include alphanumeric codes such as VERFYPATENT.*

The text provides information about a medication called afamitresgene autoleucel, branded as Tecelra®. It includes a patient's unique identifiers such as MAN, COID, First Name, Last Name, DOB, and DIN for tracking and administration purposes. Additionally, there is a reference number (L8L00036Rev00) with an expiration date (31.Dec-2024) and lot number. The text emphasizes on confirming patient identifiers before administering the medication.*